Acute Myeloid Leukemia Archives - Cancer Therapy Advisor

Biomarker detects early-stage lung cancer.

Hematologic Cancers

Immunotherapeutic Potential of RNA-Modifying Drugs and MicroRNAs in Acute Myeloid Leukemia

By

Lauren Dembeck, PhD

August 2, 2021

Researchers reviewed epitranscriptomics and the prospects of precision medicines that target AML-associated genes.

A 10% reduction in calorie intake during the first month of treatment shows promise for augmenting chemotherapy treatment in children and adolescents with ALL.

Hematologic Cancers

CPX-351 May Provide Survival Benefit in Older Patients With High-Risk or Secondary Acute Myeloid Leukemia

By

Sucharita Mistry, PhD

July 20, 2021

The 5-year survival rate was longer with CPX-351 than with conventional chemotherapy.

Preparing a child to receive chemotherapy.

Hematologic Cancers, News

Gemtuzumab Ozogamicin Can Improve Outcomes in Pediatric KMT2A-Rearranged Acute Myeloid Leukemia

By

Sucharita Mistry, PhD

June 17, 2021

Gemtuzumab ozogamicin improved event-free survival and disease-free survival.

EHA2021 Virtual Congress

At-Home Chemotherapy Appears Safe, Feasible for Acute Myeloid Leukemia, Myelodysplastic Syndromes

By

Jonathan Goodman, MPhil

June 11, 2021

Roughly a quarter of treatment cycles were administered solely as home-based treatment, with no hospital admissions required.

EHA2021 Virtual Congress

Relapsed/Refractory, IDH2-Mutated AML: Olutasidenib Shows Promise

By

Jonathan Goodman, MPhil

June 11, 2021

IDH1 differentiation syndrome of any grade was noted in 14% of patients, with 1 fatal case.

A patient with cancer receives palliative care.

ASCO 2021

Integrated Palliative Care Improves Symptoms, Coping in Patients Hospitalized for Acute Myeloid Leukemia Treatment

By

Joyce Pagan

June 8, 2021

Analysis findings that demonstrated the benefit of an integrated palliative care intervention for hospitalized patients with AML were presented at the 2021 ASCO Annual Meeting.

ASCO 2021

Anti-CLL1 CAR T Cells Produce Responses in Pediatric Acute Myeloid Leukemia

By

Leah Lawrence

June 6, 2021

Eight patients had a complete response within 1 month of infusion.

Researchers are attempting to identify treatment strategies that would allow for shorter therapy dur

Multiple Myeloma

Epigenetic Analysis Outlines Factors Predicting HMA Response in MDS, AML

By

Jonathan Goodman, MPhil

May 28, 2021

Researchers sought to determine what factors may help predict what patients with MDS or AML would respond to treatment with azacitidine.

Peripheral blood sample MRD assessment will likely come into routine clinical use in the next few years, according to an expert who specializes in CLL.

Hematologic Cancers

Whole-Genome Sequencing Shows Promise for Risk Stratification in AML, MDS

By

Jonathan Goodman, MPhil

April 26, 2021

Researchers sought to determine whether whole-genome sequencing may be a better risk stratification tool compared with conventional cytogenetic analysis.

While survival rates of pediatric patients with cancer are greatly improved, researchers and clinici

Pediatric Cancer

Risk Factors for Pediatric Hemorrhagic Cystitis Following HCT

By

Leah Lawrence

April 14, 2021

Investigators conducted a study to determine the incidence and clinical course of BK virus hemorrhagic cystitis in children undergoing hematopoietic cell transplantation.